Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

4048 - Contrast enhancement in low grade gliomas: a classic prognostic factor in the molecular age

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Topics

Pathology/Molecular Biology

Tumour Site

Central Nervous System Malignancies

Presenters

Florian Castet

Citation

Annals of Oncology (2018) 29 (suppl_8): viii122-viii132. 10.1093/annonc/mdy273

Authors

F. Castet1, E. Alanya2, M. Gil-Gil1, N. Vidal3, C. Izquierdo4, C. Mesia1, J. Bruna5

Author affiliations

  • 1 Medical Oncology, Institut Català d'Oncologia Hospital Duran i Reynals, 08907 - Barcelona/ES
  • 2 Medical Oncology And Radiotherapy, Edgardo Rebagliati Martins National Hospital - EsSalud, Lima 34 - Lima/PE
  • 3 Anatomia Patològica, Hospital Universitari de Bellvitge, 08908 - Hospitalet de Llobregat/ES
  • 4 Service De Neuro-oncologie, Hospices Civils de Lyon, Groupe Hospitalier Est, 69394 - Lyon/FR
  • 5 Neurology, Hospital Universitari de Bellvitge, 08908 - Hospitalet de Llobregat/ES
More

Resources

Abstract 4048

Background

Contrast enhancement (CE) is described in 10-60% of low grade gliomas (LGG). Its prognostic significance is controversial, and its correlation with IDH mutations and 1p/19q codeletion is unknown. The aim of this study is to investigate whether CE is associated with molecular characteristics of LGG and elucidate its prognostic value.

Methods

All confirmed histological cases of LGG diagnosed in a single institution between years 2000-2016 were retrospectively reviewed (n = 104). Clinical, radiological and molecular factors were collected. Spinal and brainstem localization, only-biopsied tumours with ring-like enhancement and incomplete medical records were excluded. 1p/19 codeletion analysis was performed by FISH, IDH was performed by immunohistochemistry. IDH wild-type tumours were confirmed with qPCR. Overall survival (OS) was estimated by Kaplan-Meier method.

Results

We included 89 patients, with a median follow-up of 73.3 months. Mean age was 41.6 years, and 65.2% were male. CE was present on 25.8% of preoperative MRI, and 25.3% of patients were considered high-risk according to Pignatti score. Most were astrocytomas (67.4%) and 84.4% were surgically removed. IDH mutation was found in 66.7% of tumour samples, and 17.9% had a 1p/19q codeletion. No differences were observed amongst CE and non-CE groups, apart from age (46.6 vs 39.9 years, respectively; p = 0.041). IDH mutation (p = 0.776) and 1p/19q codeletion (p = 0.512) were evenly distributed. On univariate analysis, size >6cm (p = 0.002), CE (p = 0.026), extent of resection (p = 0.008), Pignatti score (p = 0.002) and IDH mutation (p = 0.003) were significantly associated to OS. On multivariate analysis, only CE (p = 0.009) and IDH status (p = 0.005) were independently associated to OS.

Conclusions

CE in LGG provides complementary and independent prognostic information to IDH and 1p/19q codeletion. Its contribution to treatment decisions requires further exploration in larger prospective cohort studies.

Clinical trial identification

Legal entity responsible for the study

Unidad de Neuro-Oncología, Institut Català d'Oncologia.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.